News

HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTCPK: UEEC, “UHP”) today announced that it has submitted documents requested by the FDA in conjunction with its PMA (Class III) application to use HemoStyp in internal surgeries. The company expects the FDA to grant approval to its PMA (Class III) application or request additional information within 30 days. […]

HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTCPK: UEEC, “UHP”) today announced that it has uploaded the full results of its Human Trial study, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, to the ClinicalTrials.gov website; these results are expected to be made available to the public within 7-14 days. […]

HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTC: UEEC) (“UHP” or the “Company”), today announced that it has filed a non-provisional patent application with the U.S. Patent & Trademark Office for the hydrocolloid (gel) format of its HemoStyp oxidized regenerated cellulose product, and has also filed a separate application under the Patent Cooperation Treaty with the […]

HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTC: UEEC), (“UHP” or the “company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,557,874 Oct 15,2013) for the healthcare and wound care sectors, today announced that is has recently received correspondence from the FDA regarding its current PMA class […]

HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTC: UEEC) (UHP or the company) today announced that it is proceeding with its Premarket Approval (PMA) application for Class III approval to the FDA for HemoStyp®. In this current difficult environment, UHP has been working continuously with the FDA to advance its application, and has been working towards […]